7.84
-0.19 (-2.37%)
| Penutupan Terdahulu | 8.03 |
| Buka | 8.09 |
| Jumlah Dagangan | 2,026,948 |
| Purata Dagangan (3B) | 1,931,964 |
| Modal Pasaran | 1,977,538,048 |
| Harga / Pendapatan (P/E Ke hadapan) | 370.37 |
| Harga / Jualan (P/S) | 2.63 |
| Harga / Buku (P/B) | 2.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Nov 2024 |
| Margin Keuntungan | -81.13% |
| Margin Operasi (TTM) | -23.09% |
| EPS Cair (TTM) | -1.67 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -2.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 100.03% |
| Nisbah Semasa (MRQ) | 10.74 |
| Aliran Tunai Operasi (OCF TTM) | 29.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 8.86 M |
| Pulangan Atas Aset (ROA TTM) | -1.61% |
| Pulangan Atas Ekuiti (ROE TTM) | -42.93% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Maravai LifeSciences Holdings, | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | 0.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.40 |
|
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.45% |
| % Dimiliki oleh Institusi | 102.69% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 13.00 (RBC Capital, 65.82%) | Beli |
| Median | 9.00 (14.80%) | |
| Rendah | 4.25 (Goldman Sachs, -45.79%) | Jual |
| Purata | 8.75 (11.61%) | |
| Jumlah | 2 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 5.08 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 05 Dec 2024 | 4.25 (-45.79%) | Jual | 5.09 |
| 08 Oct 2024 | 7.00 (-10.71%) | Pegang | 7.68 | |
| Baird | 08 Nov 2024 | 9.00 (14.80%) | Beli | 5.08 |
| RBC Capital | 08 Nov 2024 | 13.00 (65.82%) | Beli | 5.08 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ECKERT R ANDREW | 5.58 | - | 134,409 | 750,002 |
| LUCIER GREGORY T | 5.43 | 5.43 | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 134,409 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 750,002 | |||
| Purata Pembelian Keseluruhan ($) | 5.51 | |||
| Purata Jualan Keseluruhan ($) | 5.43 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ECKERT R ANDREW | Pengarah | 16 Dec 2024 | Diperolehi (+) | 134,409 | 5.58 | 750,002 |
| LUCIER GREGORY T | Pengarah | 09 Dec 2024 | Dibuang (-) | 20,645 | 5.43 | 112,102 |
| LUCIER GREGORY T | Pengarah | 09 Dec 2024 | Diperolehi (+) | 20,645 | 5.43 | 112,102 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Dec 2024 | Pengumuman | Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors |
| 12 Nov 2024 | Pengumuman | Maravai LifeSciences Announces November 2024 Investor Conference Schedule |
| 07 Nov 2024 | Pengumuman | Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research |
| 07 Nov 2024 | Pengumuman | Maravai LifeSciences Reports Third Quarter 2024 Financial Results |
| 15 Oct 2024 | Pengumuman | Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024 |
| 24 Sep 2024 | Pengumuman | TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |